What are the side effects of ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib (Ibrutinib) is an anti-cancer drug. Although it is very effective in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), etc., it may also cause some side effects. The following is a detailed introduction to the possible side effects of ibrutinib:

1. Bleeding: Ibrutinib may interfere with platelet function, leading to an increased risk of bleeding. Patients may experience symptoms such as skin congestion, nose bleeding, gum bleeding, and increased menstrual flow. Bleeding needs to be monitored closely while taking ibrutinib, especially before and after surgery or other invasive procedures.

2. Infection: Ibrutinib may affect immune system function and increase the risk of infection. Patients may experience infection symptoms such as fever, cough, sore throat, and frequent urination. If signs of infection appear, seek prompt medical attention and receive appropriate treatment.

3. Hypertension: Ibrutinib may cause blood pressure to rise. Patients need to monitor their blood pressure regularly and cooperate with their doctors for adjustments and treatment.

4. Diarrhea and nausea: Ibrutinib may cause digestive system problems, and patients often experience diarrhea, nausea, vomiting and other discomforts. Maintain good eating habits, avoid spicy food, and properly handle these symptoms under the guidance of a doctor.

5. Fatigue and weakness: Ibrutinib may cause physical fatigue and weakness. Patients need to pay attention to rest and reasonably arrange activities and work according to their own conditions.

6. Skin reactions: Ibrutinib may cause skin reactions, such as rash, dryness, itching, etc. Inform your doctor promptly and take appropriate skin care measures according to your doctor's recommendations.

In addition, ibrutinib may cause other side effects, including headache, joint pain, muscle pain, vision problems, etc. Patients should have regular follow-up visits while using ibrutinib and inform their doctors of any symptoms of discomfort so that the treatment plan can be adjusted in a timely manner or corresponding supportive treatment can be provided.